HCW Biologics Inc (HCWB) News

Form D - Notice of Exempt Offering of Securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 8-K - Current report

Form 8-K - Current report

Form 424B2 - Prospectus [Rule 424(b)(2)]

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ:...

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”...

Form 8-K - Current report

Form 8-K/A - Current report: [Amend]

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

This release has made a correction to a release issued under the same headline on August 14, 2024, by HCW...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]